Roche sketches out Blueprint collaboration


Drug discovery startup Blueprint Medicines has agreed a research collaboration with Roche to develop small molecule drugs aimed at cancer immunotherapy targets.

Blueprint specialises in developing molecules that interact with kinases – enzymes that add phosphate groups onto other proteins or substrate molecules. Kinases are involved in numerous cell-signalling pathways. The projects covered by this deal relate to kinases implicated in modulating our immune system’s response to tumours. Roche is one of a host of companies developing new cancer medicines that harness the immune system.

The deal is heavily performance-related. Roche will pay $45 million (£31 million) up front, with up to $965 million on offer as projects progress, plus royalties on any products that make it to market.


Related Content

Pharma queues up for checkpoint inhibitor collaborations

3 July 2015 Business

news image

Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits

Viral cancer therapy approved in the US

11 November 2015 Business

news image

T-Vec is the first approved oncolytic virus, but its limited treatment scope means it is unlikely to become a blockbuster

Most Commented

WHO clarifies glyphosate risks

23 May 2016 Business

news image

UN and WHO panel conclude the herbicide glyphosate is ‘unlikely’ to cause cancer at realistic exposure levels

Crawling chemical system acts as if it’s alive

24 May 2016 Research

news image

Intriguing globule that moves, eats and defecates